HomePipelinePNB-081Opiate Management

PNB-081

Opiate Management

PNB-081 for Opiate Pain Management

Molecule
PNB-081
Development status
IND ready
Therapeutic area
CNS & addiction
Biological action
CCK-A antagonist
Therapeutic target
Cholecystokinin Receptors A, CCK1
Therapeutic indication
Pain Management in combination with opioids
Secondary indications
Opiate sparing agent treatment of Opiate Addiction

Stage of development

  • PNB-081

    Opiate ManagementCCK-A antagonist

Graph of the stage of development of PNB-081 in Opiate Management. Horizontal axis: clinical development stage, from Preclinical to Phase 3. Vertical axis: molecule and indication. Each marker opens the programme's indication, biological action, stage and status.
Information about target and disease:

Opiate addition is epidemic in the US and CCK antagonists worked clinically in phase 2 for opiate potentiation, thus sparing doses of the opiate drug without developing tolerance to the opiate drug.

Anatomical studies have shown that the distribution of CCK-8 and CCK receptors parallels that of endogenous opioids and opioid receptors in the pain-processing regions in both the brain and the spinal cord. This overlapping distribution triggered numerous investigations on the role of CCK in nociception.

Preclinically in rats the combination of opioids with selective CCK1 receptor antagonists enhanced the analgesic effects of morphine in rodents, which was confirmed by many groups. In a phase 2 trial, the CCK1 antagonist devazepide (Devacade), but not the CCK2 antagonist Polykade, significantly improved pain relief at a higher dose in 50% of patients.

Preclinical studies:

In the hot plate paw withdrawal model, 0.5 mg/kg PNB-081 analog was administered intraperitoneally in conjunction with 40 mg/kg tramadol, a widely used opioid, subcutaneously to mice and the latency time was measured one hour after administration of the drugs. PNB-081 and PNB-028 potentiated the analgesic effect of tramadol into the analgesic efficacy of morphine.

Subsequent experiments were performed to determine the dose and time response of PNB molecule to understand the longevity of the effect. Mice administered with PNB analog at 1 mg/kg and 2 mg/kg of morphine demonstrated a sustained pain tolerance and these effects were either comparable or superior to the effect observed with a high morphine dose (8, 16 mg/kg).

In order to confirm the prevention of opiate tolerance, PNB analog was orally administered at 1 mg/kg in mice and 4 mg/kg of morphine. The analgesic effect of morphine faded out within days and 1 mg/kg concomitantly administered with 4 mg/kg of morphine showed an unchanged response time over many days. No tolerance to morphine was observed. Further extended studies clearly demonstrated, that PNB analogue at 1 mg/kg P.O. was very effective in preventing opiate tolerance and is orally bioavailable.

Preclinical development studies:

PNB-081 is in terms of binding profile equivalent to devazepide, but has excellent pharmacokinetics and oral bioavailability, as well as very high membrane penetration.

DMPK studies with PNB-081 indicated that the molecule was highly stable in rat, dog, and human liver microsomes. PNB-081 was also highly available in rats with a >25% bioavailability. Other studies, including CaCo2 permeability and plasma protein binding demonstrated favorable druggable properties.

Intellectual property:

Since PNB-081 belongs to the same class as PNB-028 or PNB-001, its chemical structure is also well protected until 2037 (including 5 years of extension) in most of the countries around the World.

About PNB-081

Preclinical completed · IND ready

A closely related molecule addressing Obesity at low doses and, at higher doses, acting as an opiate-sparing agent. It may also substitute for PNB-028 in Pancreatitis.

PNB-081 full profile

Other indications of PNB-081

Metabolic Diseases

All molecules

Interested in a programme?

PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.